Melissa Rewolinski - May 23, 2024 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director
Signature
/s/ David C. Hastings as attorney-in-fact for Melissa V. Rewolinski
Stock symbol
ABUS
Transactions as of
May 23, 2024
Transactions value $
$0
Form type
4
Date filed
5/24/2024, 04:10 PM
Previous filing
Jul 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +67K $0.00 67K May 23, 2024 Common Shares 67K $3.28 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2 The option is fully vested and exercisable as of the date of the grant.